FDA asks adcomm if AstraZeneca needs another study on Imfinzi before and after lung cancer surgery
The FDA outlined concerns of overtreatment in AstraZeneca’s clinical trial of its immune checkpoint drug before and after lung cancer surgery ahead of a public …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
